Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

View post:
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *